PRA Health Sciences (NASDAQ: PRAH) is one of 197 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare PRA Health Sciences to related companies based on the strength of its valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.
Volatility & Risk
PRA Health Sciences has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, PRA Health Sciences’ rivals have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.
This table compares PRA Health Sciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|PRA Health Sciences||5.15%||21.17%||7.23%|
|PRA Health Sciences Competitors||-3,989.23%||-119.42%||-44.20%|
Earnings and Valuation
This table compares PRA Health Sciences and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|PRA Health Sciences||$1.70 billion||$250.95 million||52.54|
|PRA Health Sciences Competitors||$207.83 million||-$2.34 million||0.17|
PRA Health Sciences has higher revenue and earnings than its rivals. PRA Health Sciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
98.4% of PRA Health Sciences shares are held by institutional investors. Comparatively, 46.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 2.1% of PRA Health Sciences shares are held by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a breakdown of recent recommendations for PRA Health Sciences and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|PRA Health Sciences||0||1||9||0||2.90|
|PRA Health Sciences Competitors||469||2235||6130||118||2.66|
PRA Health Sciences presently has a consensus target price of $85.00, indicating a potential upside of 4.37%. As a group, “Biotechnology & Medical Research” companies have a potential downside of 0.02%. Given PRA Health Sciences’ stronger consensus rating and higher possible upside, equities analysts plainly believe PRA Health Sciences is more favorable than its rivals.
PRA Health Sciences beats its rivals on 10 of the 13 factors compared.
About PRA Health Sciences
PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company’s service offerings include product registration, strategic solutions and early development services.
Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.